secwatch.observer — SEC 8-K summary
======================================

Issuer:     BICYCLE THERAPEUTICS PLC (BCYC)
CIK:        0001761612
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001104659-24-086085
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bicycle Therapeutics Q2 net loss $39.8M; cash $961.4M after $555M PIPE
----------------------------------------------------------------------

- Net loss of $39.8M ($0.77 loss per share) vs $42.6M ($1.41 loss per share) in Q2 2023; R&D expense $40.1M.
- Cash and cash equivalents $961.4M as of June 30, 2024, up from $526.4M at Dec 31, 2023, after $555M PIPE financing.
- Pipeline focused on zelenectide pevedotin (BTC) and BT5528; four abstracts accepted for ESMO 2024.
- Jennifer Perry promoted to CSO & head of commercial; Nick Keen transitions to advisor; new Clinical Advisory Board formed.
- Repaid $31.9M Hercules loan in July 2024 ahead of maturity; financial runway extended into 2H 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761612/000110465924086085/0001104659-24-086085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761612/000110465924086085/tm2420860d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-086085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer